{"key":"op_713_IT","page":{"url":"https://us-uk.bookimed.com/clinics/country=italy/procedure=immunotherapy-for-breast-cancer/","procedure":{"id":713,"slug":"immunotherapy-for-breast-cancer","name":"Immunotherapy for breast cancer","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"oncology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":127,"iso":"IT","name":"Italy"},"currency":"USD","data_date":"2026-10-03"},"pages":{"clinics_url":"https://us-uk.bookimed.com/clinics/country=italy/procedure=immunotherapy-for-breast-cancer/","cost_url":"https://us-uk.bookimed.com/clinics/country=italy/procedure=immunotherapy-for-breast-cancer/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":18000,"to":34000,"avg":{"status":"missing","reason":"no_offers"},"us":{"from":60000,"to":150000},"uk":{"from":24000,"to":48000},"by_technique":[{"technique":"PD-1 inhibitor with chemotherapy","technique_id":"pd-1-inhibitor","price_from":18000,"currency":"USD","source":"estimate","date":"2026-11-17"},{"technique":"PD-1/PD-L1 inhibitor plus chemotherapy, metastatic","technique_id":"pd-1","price_from":20000,"currency":"USD","source":"estimate","date":"2026-11-17"}],"by_city":[{"city":"Milan","from":22000}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"status":"missing","reason":"no_offers"},"comparison":[{"country_iso":"UA","from":6500,"to":15000},{"country_iso":"FR","from":14000,"to":30000},{"country_iso":"GB","from":24000,"to":48000},{"country_iso":"US","from":60000,"to":150000},{"country_iso":"IL","from":28000,"to":48000},{"country_iso":"TR","from":8000,"to":16000},{"country_iso":"MX","from":12000,"to":25000},{"country_iso":"DE","from":14000,"to":30000},{"country_iso":"CA","from":28000,"to":65000},{"country_iso":"AE","from":30000,"to":65000},{"country_iso":"TH","from":5900,"to":14000},{"country_iso":"PL","from":6500,"to":13500},{"country_iso":"KR","from":14000,"to":27000},{"country_iso":"CZ","from":9000,"to":20000},{"country_iso":"AT","from":18000,"to":36000},{"country_iso":"ES","from":2200,"to":28000},{"country_iso":"CN","from":14000,"to":36000},{"country_iso":"AU","from":16000,"to":29000},{"country_iso":"IN","from":14000,"to":23000},{"country_iso":"MY","from":14000,"to":30000},{"country_iso":"VN","from":14000,"to":27000},{"country_iso":"BR","from":9000,"to":20000}],"base_country":"US","base_is_fallback":false},"savings":{"pct":70,"variant":">=15%"},"package":{"included":{"status":"missing","reason":"no_offers"},"excluded":{"status":"missing","reason":"no_offers"},"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":1,"items":[{"id":303,"name":"San Raffaele","city":"Milan","rating":4.6,"reviews_count":71,"accreditations":["Scientific Institute for Research and Healthcare Accrediatation","World's Best Hospitals 2021 by Newsweek"],"rank":1,"has_procedure":true,"why_ranked":"Head of breast cancer group leads immunotherapy research, with over 100 clinical trials conducted. 12,000 cancer patients treated annually, including complex breast cancer cases.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":1,"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":353,"slug":"milan","name":"Milan","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":22000,"profile":{"city_type":"Capital and largest city of Lombardy","access":["Malpensa Airport (MXP), 49 km from Milan","Linate Airport (LIN), 7 km from the city center"],"sources":["https://en.wikipedia.org/wiki/Milan","https://en.wikipedia.org/wiki/Milan_Malpensa_Airport","https://en.wikipedia.org/wiki/Linate_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":{"status":"missing","reason":"no_offers"},"active_with_related":{"status":"missing","reason":"no_offers"},"hospital_nights_median":{"status":"missing","reason":"no_offers"},"days_in_country_median":{"status":"missing","reason":"no_offers"},"top_offers":{"status":"missing","reason":"no_offers"},"packages":{"status":"missing","reason":"no_offers"},"related_packages":{"status":"missing","reason":"no_offers"},"other_packages":{"status":"missing","reason":"no_offers"}},"medical":{"indications":["High-risk stage II-III early triple-negative breast cancer, with chemotherapy","Metastatic PD-L1-positive triple-negative breast cancer, with chemotherapy"],"contraindications":["Active autoimmune disease requiring systemic immunosuppression","History of organ transplant","Prior severe immune-related adverse event","Active uncontrolled infection","Pregnancy or breastfeeding","History of interstitial lung disease or pneumonitis","Long-term high-dose corticosteroid use"],"operation_hours":{"min":2,"max":6,"unit":"hours","qualifier":"Per visit; longer when combined with chemotherapy and pre-infusion tests."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":9,"max":17,"unit":"visits","qualifier":"Infusions every 3-6 weeks for about a year, usually with chemotherapy."},"stages":[{"code":"neoadjuvant","label":"Immunotherapy with chemotherapy before surgery","after":{"min":0,"max":168,"unit":"days","qualifier":"About 5.5 months of combined cycles."}},{"code":"surgery","label":"Surgery at home or local center","after":{"min":170,"max":210,"unit":"days","qualifier":"Timing set by treating oncology team."}},{"code":"adjuvant","label":"Adjuvant immunotherapy continuation","after":{"min":220,"max":365,"unit":"days","qualifier":"Continues up to about a year in total."}}],"qualifier":"Typical early high-risk triple-negative protocol; later cycles often continue at home."},"hospital_nights":{"value":{"min":0,"max":0,"unit":"nights","qualifier":"Infusions are given as outpatient visits without overnight stay."},"source":"parsed_details"},"treatment_conditions":["outpatient"],"rehabilitation_days":{"status":"missing","reason":"not_collected"},"fly_home_after_days":{"min":1,"max":3,"unit":"days","qualifier":"Depends on infusion reactions and chemotherapy blood counts."},"back_to_work_days":{"min":2,"max":7,"unit":"days","qualifier":"Fatigue after infusion and concurrent chemotherapy often limit work; many patients work part-time."},"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"Light activity as tolerated; intensity depends on fatigue and chemotherapy side effects."},"final_result_months":{"min":6,"max":12,"unit":"months","qualifier":"Response assessed after neoadjuvant phase and surgery; full course lasts about a year."},"result_longevity":"Benefit duration varies; in responders, immune-mediated disease control can persist for years after treatment ends.","main_risks":["Immune-related organ inflammation; some severe or permanent.","Infusion reactions are possible with some agents.","Added toxicity when combined with chemotherapy."],"complication_rate_pct":{"min":60,"max":80,"unit":"percent","qualifier":"Grade 3-4 adverse events including chemotherapy toxicity; immune-related events of grade 3+ about 10-15%."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Event-free survival at 5 years","value":81,"horizon":"5 years","source":{"status":"missing","reason":"not_collected"},"evidence_status":"proven"},"scars":"None; no incisions.","pain":"Infusion causes only cannula discomfort. Fatigue, joint aches or rash may occur; combined chemotherapy adds further discomfort.","preparation":["Confirm receptor status and PD-L1 result","Baseline blood, liver, thyroid and cortisol tests","Baseline imaging","Review autoimmune and transplant history","Screen for infections such as hepatitis","Pregnancy test if applicable"],"recovery_timeline":[{"phase":"Infusion day","description":"Infusion lasts 30-60 minutes for immunotherapy, longer with chemotherapy; monitored for reactions.","restrictions":["Report fever, breathlessness or rash promptly"]},{"phase":"Days 1-7 after infusion","description":"Fatigue, nausea and mild flu-like symptoms are common, mainly from chemotherapy.","restrictions":["Avoid crowds if blood counts are low"]},{"phase":"Months 1-12","description":"Cycles repeat every 3-6 weeks; immune-related effects may appear at any time, even after completion.","restrictions":["Do not start new medicines without oncologist approval"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":21,"max":42,"unit":"days","qualifier":"Blood, thyroid and liver tests before each cycle to detect immune-related effects."}},{"purpose":"result_review","requirement":"routine","after":{"min":84,"max":126,"unit":"days","qualifier":"Imaging or response review after several cycles."}},{"purpose":"other","requirement":"conditional","after":{"min":0,"max":7,"unit":"days","qualifier":"Urgent review within days if immune-related side effects suspected."}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that your breast cancer type is one for which immunotherapy is used, such as triple-negative breast cancer","scope":"procedure","source":{"url":"https://www.cancer.gov/types/breast/patient/breast-treatment-pdq","host":"cancer.gov","quote":"Immunotherapy may be used to treat triple-negative breast cancer.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C2","text":"Check that you and the cancer care team decide the treatment plan together, which may include more than one treatment type","scope":"treatment_type","source":{"url":"https://www.cancer.gov/types/breast/patient/breast-treatment-pdq","host":"cancer.gov","quote":"You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C3","text":"Ask how tests will track whether immunotherapy is working, such as tumor size and blood work","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"These tests will measure the size of your tumor and look for changes in your blood work.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C4","text":"Ask which side effects are possible, since immunotherapy can act against healthy cells and tissues in your body","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"Immunotherapy can cause side effects, many of which happen when the immune system that has been revved-up to act against the cancer also acts against healthy cells and tissues in your body.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C5","text":"Check the schedule of regular check-ups during and after treatment","scope":"treatment_type","source":{"url":"https://www.nhs.uk/conditions/breast-cancer/treatment/","host":"nhs.uk","quote":"You'll have regular check-ups during and after any treatments.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C6","text":"Check how to contact the specialists about symptoms or side effects between scheduled check-ups","scope":"treatment_type","source":{"url":"https://www.nhs.uk/conditions/breast-cancer/treatment/","host":"nhs.uk","quote":"If you have any symptoms or side effects that you are worried about, talk to your specialists.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Promise that immunotherapy will produce a result, when only a small portion of patients respond","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"Only a small portion of people who receive immunotherapy will respond to the treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"F2","text":"Offer that does not take your individual preferences into account when choosing the treatment","scope":"treatment_type","source":{"url":"https://www.nice.org.uk/guidance/ng101","host":"nice.org.uk","quote":"It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"F3","text":"An offer that describes no follow-up check-ups during and after treatment is missing a standard element of care","scope":"treatment_type","source":{"url":"https://www.nhs.uk/conditions/breast-cancer/treatment/","host":"nhs.uk","quote":"You'll have regular check-ups during and after any treatments.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Severe allergic reaction","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects","host":"cancer.gov","quote":"Some types of immunotherapy may cause severe or fatal allergic and inflammation-related reactions.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"W2","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects","host":"cancer.gov","quote":"fever chills weakness dizziness nausea or vomiting muscle or joint aches fatigue headache trouble breathing low or high blood pressure","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"W3","text":"Heart palpitations","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects","host":"cancer.gov","quote":"swelling and weight gain from retaining fluid heart palpitations s inus congestion diarrhea infection organ inflammation","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects","host":"cancer.gov","quote":"fever chills weakness dizziness nausea or vomiting muscle or joint aches fatigue headache trouble breathing low or high blood pressure","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Home doctor needs the clinic's follow-up recommendations in a written discharge summary","document":"discharge summary","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"When you have treatment abroad, you must ask the treatment provider for their follow-up recommendations documented within a written discharge summary in English.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Receptor status test","aliases":["Receptor status test","receptor status"],"kind":"lab","origin":[{"field":"preparation","text":"Confirm receptor status and PD-L1 result"},{"field":"initial_assessment_documents","text":"Biopsy pathology report with receptor status"}],"what_it_checks":{"text":"It helps predict whether immunotherapy may work for you","source":{"url":"https://www.cancer.gov/types/breast/treatment/immunotherapy","host":"cancer.gov","quote":"Your doctor may suggest biomarker tests to help predict your response to immunotherapy.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"PD-L1 test","aliases":["PD-L1 test","PD-L1 result","PD-L1 test report","PD-L1"],"kind":"lab","origin":[{"field":"preparation","text":"Confirm receptor status and PD-L1 result"},{"field":"initial_assessment_documents","text":"PD-L1 test report"}],"what_it_checks":{"text":"Checks tumor PD-L1 level to see if immunotherapy may help","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"Your test results will show whether you have enough PD-L1 protein in your tumor for you to benefit from a specific immunotherapy medicine.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"You may need to stop certain medicines, such as blood thinners, before the test","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"You may need to stop taking certain medicines, such as blood thinners Â like aspirin, before this test.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T3","name":"Blood tests","aliases":["Blood tests","Baseline blood tests","Recent blood tests"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood, liver, thyroid and cortisol tests"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"text":"Looks for changes in blood work during immunotherapy","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"These tests will measure the size of your tumor and look for changes in your blood work.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"Liver function test","aliases":["Liver function test","liver tests","liver function","LFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood, liver, thyroid and cortisol tests"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Thyroid function test","aliases":["Thyroid function test","thyroid tests","thyroid function","TFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood, liver, thyroid and cortisol tests"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Cortisol test","aliases":["Cortisol test","cortisol tests","cortisol"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood, liver, thyroid and cortisol tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Hepatitis screening test","aliases":["Hepatitis screening test","hepatitis","HBV","HCV"],"kind":"lab","origin":[{"field":"preparation","text":"Screen for infections such as hepatitis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"Pregnancy test","aliases":["Pregnancy test","hCG"],"kind":"lab","origin":[{"field":"preparation","text":"Pregnancy test if applicable"}],"what_it_checks":{"text":"Flags a fetus at risk, since immunotherapy is usually avoided","source":{"url":"https://www.cancer.gov/types/breast/breast-cancer-during-pregnancy","host":"cancer.gov","quote":"Hormone therapy, targeted therapy, and immunotherapy are usually not given to pregnant or nursing women because these treatments are harmful to a fetus or a nursing baby.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"PET-CT scan","aliases":["PET-CT scan","PET-CT"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or CT scan reports"}],"what_it_checks":{"text":"Stages breast cancer; may be dangerous for a developing fetus","source":{"url":"https://www.cancer.gov/types/breast/breast-cancer-during-pregnancy","host":"cancer.gov","quote":"Some tests, such as CT or PET-CT scans that are used to stage breast cancer in women who aren't pregnant, may be dangerous for a developing fetus or a nursing baby due to radiation or use of dyes or radioactive tracers.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T10","name":"CT scan","aliases":["CT scan","CT","CT scan reports"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or CT scan reports"}],"what_it_checks":{"text":"Stages breast cancer; may be dangerous for a developing fetus","source":{"url":"https://www.cancer.gov/types/breast/breast-cancer-during-pregnancy","host":"cancer.gov","quote":"Some tests, such as CT or PET-CT scans that are used to stage breast cancer in women who aren't pregnant, may be dangerous for a developing fetus or a nursing baby due to radiation or use of dyes or radioactive tracers.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-17","next_check_at":"2027-11-17","version":1},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"},"visit_and_day":{"status":"ok","has_procedure_day":true,"items":[{"id":"V1","text":"Immunotherapy may be given in a doctor's office, a clinic, or an outpatient unit in a hospital","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"You may receive immunotherapy in a doctor’s office, clinic, or outpatient unit in a hospital.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},{"id":"V2","text":"Outpatient treatment means the patient does not stay overnight in the hospital","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"Outpatient means you do not spend the night in the hospital.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},{"id":"V3","text":"Immunotherapy treatment may be scheduled every day, every week, or every month","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"You may have treatment every day, week, or month.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},{"id":"V4","text":"The doctor checks the patient often with physical exams and asks how the patient feels","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"He or she will give you physical exams and ask you how you feel.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}],"checked_at":"2026-11-17","next_check_at":"2027-11-17","version":1},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":2,"max":7,"unit":"days","qualifier":"Fatigue after infusion and concurrent chemotherapy often limit work; many patients work part-time."},"complication_rate_pct":{"min":60,"max":80,"unit":"percent","qualifier":"Grade 3-4 adverse events including chemotherapy toxicity; immune-related events of grade 3+ about 10-15%."},"contraindications":["Active autoimmune disease requiring systemic immunosuppression","History of organ transplant","Prior severe immune-related adverse event","Active uncontrolled infection","Pregnancy or breastfeeding","History of interstitial lung disease or pneumonitis","Long-term high-dose corticosteroid use"],"days_in_clinic":{"min":0,"max":0,"unit":"nights","qualifier":"Infusions are given as outpatient visits without overnight stay."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"Light activity as tolerated; intensity depends on fatigue and chemotherapy side effects."},"final_result_months":{"min":6,"max":12,"unit":"months","qualifier":"Response assessed after neoadjuvant phase and surgery; full course lasts about a year."},"fly_home_after_days":{"min":1,"max":3,"unit":"days","qualifier":"Depends on infusion reactions and chemotherapy blood counts."},"follow_up_visits":[{"purpose":"assessment","after":{"min":21,"max":42,"unit":"days","qualifier":"Blood, thyroid and liver tests before each cycle to detect immune-related effects."},"requirement":"routine"},{"purpose":"result_review","after":{"min":84,"max":126,"unit":"days","qualifier":"Imaging or response review after several cycles."},"requirement":"routine"},{"purpose":"other","after":{"min":0,"max":7,"unit":"days","qualifier":"Urgent review within days if immune-related side effects suspected."},"requirement":"conditional"}],"indications":["High-risk stage II-III early triple-negative breast cancer, with chemotherapy","Metastatic PD-L1-positive triple-negative breast cancer, with chemotherapy"],"main_risks":["Immune-related organ inflammation; some severe or permanent.","Infusion reactions are possible with some agents.","Added toxicity when combined with chemotherapy."],"pain":"Infusion causes only cannula discomfort. Fatigue, joint aches or rash may occur; combined chemotherapy adds further discomfort.","preparation":["Confirm receptor status and PD-L1 result","Baseline blood, liver, thyroid and cortisol tests","Baseline imaging","Review autoimmune and transplant history","Screen for infections such as hepatitis","Pregnancy test if applicable"],"recovery_timeline":[{"phase":"Infusion day","description":"Infusion lasts 30-60 minutes for immunotherapy, longer with chemotherapy; monitored for reactions.","restrictions":["Report fever, breathlessness or rash promptly"]},{"phase":"Days 1-7 after infusion","description":"Fatigue, nausea and mild flu-like symptoms are common, mainly from chemotherapy.","restrictions":["Avoid crowds if blood counts are low"]},{"phase":"Months 1-12","description":"Cycles repeat every 3-6 weeks; immune-related effects may appear at any time, even after completion.","restrictions":["Do not start new medicines without oncologist approval"]}],"rehabilitation_days":null,"result_longevity":"Benefit duration varies; in responders, immune-mediated disease control can persist for years after treatment ends.","revision_rate_pct":null,"scars":"None; no incisions.","sessions_or_stages":{"sessions":{"min":9,"max":17,"unit":"visits","qualifier":"Infusions every 3-6 weeks for about a year, usually with chemotherapy."},"stages":[{"code":"neoadjuvant","label":"Immunotherapy with chemotherapy before surgery","after":{"min":0,"max":168,"unit":"days","qualifier":"About 5.5 months of combined cycles."}},{"code":"surgery","label":"Surgery at home or local center","after":{"min":170,"max":210,"unit":"days","qualifier":"Timing set by treating oncology team."}},{"code":"adjuvant","label":"Adjuvant immunotherapy continuation","after":{"min":220,"max":365,"unit":"days","qualifier":"Continues up to about a year in total."}}],"qualifier":"Typical early high-risk triple-negative protocol; later cycles often continue at home."},"success":{"metric":"Event-free survival at 5 years","value":81,"unit":"percent","horizon":"5 years","population":"Early high-risk triple-negative breast cancer treated with PD-1 inhibitor plus chemotherapy","evidence_status":"proven"},"techniques":[{"name":"PD-1 inhibitor with chemotherapy","suits_whom":"Early high-risk triple-negative breast cancer","recovery":"Outpatient infusions every 3 weeks; fatigue for days."},{"name":"PD-1/PD-L1 inhibitor plus chemotherapy, metastatic","suits_whom":"PD-L1-positive metastatic triple-negative breast cancer","recovery":"Outpatient infusions every 3-4 weeks until progression."}],"treatment_conditions":["outpatient"],"treatment_duration_hours":{"min":2,"max":6,"unit":"hours","qualifier":"Per visit; longer when combined with chemotherapy and pre-infusion tests."},"initial_assessment_documents":["Biopsy pathology report with receptor status","PD-L1 test report","Recent PET-CT or CT scan reports","Prior chemotherapy and surgery summary","Recent blood tests with liver and thyroid function","Record of autoimmune disease or transplant"],"travel_trips":{"min":4,"max":8,"one_trip_possible":false,"qualifier":"Neoadjuvant phase: one infusion per trip, 3-5 days; some cycles can be given at home."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that your breast cancer type is one for which immunotherapy is used, such as triple-negative breast cancer","scope":"procedure","source":{"url":"https://www.cancer.gov/types/breast/patient/breast-treatment-pdq","host":"cancer.gov","quote":"Immunotherapy may be used to treat triple-negative breast cancer.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C2","text":"Check that you and the cancer care team decide the treatment plan together, which may include more than one treatment type","scope":"treatment_type","source":{"url":"https://www.cancer.gov/types/breast/patient/breast-treatment-pdq","host":"cancer.gov","quote":"You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C3","text":"Ask how tests will track whether immunotherapy is working, such as tumor size and blood work","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"These tests will measure the size of your tumor and look for changes in your blood work.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C4","text":"Ask which side effects are possible, since immunotherapy can act against healthy cells and tissues in your body","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"Immunotherapy can cause side effects, many of which happen when the immune system that has been revved-up to act against the cancer also acts against healthy cells and tissues in your body.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C5","text":"Check the schedule of regular check-ups during and after treatment","scope":"treatment_type","source":{"url":"https://www.nhs.uk/conditions/breast-cancer/treatment/","host":"nhs.uk","quote":"You'll have regular check-ups during and after any treatments.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"C6","text":"Check how to contact the specialists about symptoms or side effects between scheduled check-ups","scope":"treatment_type","source":{"url":"https://www.nhs.uk/conditions/breast-cancer/treatment/","host":"nhs.uk","quote":"If you have any symptoms or side effects that you are worried about, talk to your specialists.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Promise that immunotherapy will produce a result, when only a small portion of patients respond","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"Only a small portion of people who receive immunotherapy will respond to the treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"F2","text":"Offer that does not take your individual preferences into account when choosing the treatment","scope":"treatment_type","source":{"url":"https://www.nice.org.uk/guidance/ng101","host":"nice.org.uk","quote":"It aims to help healthcare professionals offer the right treatments to people, taking into account the person's individual preferences.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"F3","text":"An offer that describes no follow-up check-ups during and after treatment is missing a standard element of care","scope":"treatment_type","source":{"url":"https://www.nhs.uk/conditions/breast-cancer/treatment/","host":"nhs.uk","quote":"You'll have regular check-ups during and after any treatments.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Severe allergic reaction","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects","host":"cancer.gov","quote":"Some types of immunotherapy may cause severe or fatal allergic and inflammation-related reactions.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"W2","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects","host":"cancer.gov","quote":"fever chills weakness dizziness nausea or vomiting muscle or joint aches fatigue headache trouble breathing low or high blood pressure","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"W3","text":"Heart palpitations","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects","host":"cancer.gov","quote":"swelling and weight gain from retaining fluid heart palpitations s inus congestion diarrhea infection organ inflammation","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/side-effects","host":"cancer.gov","quote":"fever chills weakness dizziness nausea or vomiting muscle or joint aches fatigue headache trouble breathing low or high blood pressure","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Home doctor needs the clinic's follow-up recommendations in a written discharge summary","document":"discharge summary","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"When you have treatment abroad, you must ask the treatment provider for their follow-up recommendations documented within a written discharge summary in English.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"You need a treatment that reaches cancer cells throughout the body","name":"Chemotherapy","source":{"url":"https://www.cancer.gov/types/breast/treatment","host":"cancer.gov","quote":"Systemic treatments , such as chemotherapy, are drugs that can reach cancer cells throughout the body.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200},"operation_id":37},{"id":"A2","text":"Your treatment needs to target the area with cancer","name":"Radiation therapy","source":{"url":"https://www.cancer.gov/types/breast/treatment","host":"cancer.gov","quote":"Local treatments , such as surgery and radiation, are directed at the area with cancer and not the whole body.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200},"operation_id":null}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"technique_details":{"status":"ok","items":[{"id":"pd-1-inhibitor","name":"PD-1 inhibitor with chemotherapy","how_it_works":{"text":"Immunotherapy is given with chemotherapy before surgery to shrink the tumor","source":{"url":"https://www.cancer.gov/types/breast/treatment/immunotherapy","host":"cancer.gov","quote":"You might get it with chemotherapy before surgery to help shrink the tumor so that it can be removed more easily during surgery.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"pd-1","name":"PD-1/PD-L1 inhibitor plus chemotherapy, metastatic","how_it_works":{"text":"Immunotherapy may be combined with chemotherapy for metastatic or recurrent breast cancer","source":{"url":"https://www.cancer.gov/types/breast/treatment/immunotherapy","host":"cancer.gov","quote":"Immunotherapy may also be given with chemotherapy for metastatic breast cancer or recurrent breast cancer that cannot be removed by surgery.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Receptor status test","aliases":["Receptor status test","receptor status"],"kind":"lab","origin":[{"field":"preparation","text":"Confirm receptor status and PD-L1 result"},{"field":"initial_assessment_documents","text":"Biopsy pathology report with receptor status"}],"what_it_checks":{"text":"It helps predict whether immunotherapy may work for you","source":{"url":"https://www.cancer.gov/types/breast/treatment/immunotherapy","host":"cancer.gov","quote":"Your doctor may suggest biomarker tests to help predict your response to immunotherapy.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"PD-L1 test","aliases":["PD-L1 test","PD-L1 result","PD-L1 test report","PD-L1"],"kind":"lab","origin":[{"field":"preparation","text":"Confirm receptor status and PD-L1 result"},{"field":"initial_assessment_documents","text":"PD-L1 test report"}],"what_it_checks":{"text":"Checks tumor PD-L1 level to see if immunotherapy may help","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"Your test results will show whether you have enough PD-L1 protein in your tumor for you to benefit from a specific immunotherapy medicine.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":{"text":"You may need to stop certain medicines, such as blood thinners, before the test","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"You may need to stop taking certain medicines, such as blood thinners Â like aspirin, before this test.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}},{"id":"T3","name":"Blood tests","aliases":["Blood tests","Baseline blood tests","Recent blood tests"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood, liver, thyroid and cortisol tests"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"text":"Looks for changes in blood work during immunotherapy","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"These tests will measure the size of your tumor and look for changes in your blood work.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"Liver function test","aliases":["Liver function test","liver tests","liver function","LFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood, liver, thyroid and cortisol tests"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Thyroid function test","aliases":["Thyroid function test","thyroid tests","thyroid function","TFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood, liver, thyroid and cortisol tests"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Cortisol test","aliases":["Cortisol test","cortisol tests","cortisol"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood, liver, thyroid and cortisol tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Hepatitis screening test","aliases":["Hepatitis screening test","hepatitis","HBV","HCV"],"kind":"lab","origin":[{"field":"preparation","text":"Screen for infections such as hepatitis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"Pregnancy test","aliases":["Pregnancy test","hCG"],"kind":"lab","origin":[{"field":"preparation","text":"Pregnancy test if applicable"}],"what_it_checks":{"text":"Flags a fetus at risk, since immunotherapy is usually avoided","source":{"url":"https://www.cancer.gov/types/breast/breast-cancer-during-pregnancy","host":"cancer.gov","quote":"Hormone therapy, targeted therapy, and immunotherapy are usually not given to pregnant or nursing women because these treatments are harmful to a fetus or a nursing baby.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"PET-CT scan","aliases":["PET-CT scan","PET-CT"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or CT scan reports"}],"what_it_checks":{"text":"Stages breast cancer; may be dangerous for a developing fetus","source":{"url":"https://www.cancer.gov/types/breast/breast-cancer-during-pregnancy","host":"cancer.gov","quote":"Some tests, such as CT or PET-CT scans that are used to stage breast cancer in women who aren't pregnant, may be dangerous for a developing fetus or a nursing baby due to radiation or use of dyes or radioactive tracers.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T10","name":"CT scan","aliases":["CT scan","CT","CT scan reports"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or CT scan reports"}],"what_it_checks":{"text":"Stages breast cancer; may be dangerous for a developing fetus","source":{"url":"https://www.cancer.gov/types/breast/breast-cancer-during-pregnancy","host":"cancer.gov","quote":"Some tests, such as CT or PET-CT scans that are used to stage breast cancer in women who aren't pregnant, may be dangerous for a developing fetus or a nursing baby due to radiation or use of dyes or radioactive tracers.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-17","next_check_at":"2027-11-17","version":1},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"},"visit_and_day":{"status":"ok","has_procedure_day":true,"items":[{"id":"V1","text":"Immunotherapy may be given in a doctor's office, a clinic, or an outpatient unit in a hospital","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"You may receive immunotherapy in a doctor’s office, clinic, or outpatient unit in a hospital.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},{"id":"V2","text":"Outpatient treatment means the patient does not stay overnight in the hospital","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"Outpatient means you do not spend the night in the hospital.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},{"id":"V3","text":"Immunotherapy treatment may be scheduled every day, every week, or every month","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"You may have treatment every day, week, or month.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}},{"id":"V4","text":"The doctor checks the patient often with physical exams and asks how the patient feels","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy","host":"cancer.gov","quote":"He or she will give you physical exams and ask you how you feel.","tier":"tier1_medical","fetched_at":"2026-11-17","http_status":200}}],"checked_at":"2026-11-17","next_check_at":"2027-11-17","version":1},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-17","next_check_at":"2027-02-15"}}},"techniques":[{"id":"pd-1-inhibitor","name":"PD-1 inhibitor with chemotherapy","how_it_works":{"id":"H1","text":"Immunotherapy is given with chemotherapy before surgery to shrink the tumor","source":{"url":"https://www.cancer.gov/types/breast/treatment/immunotherapy","host":"cancer.gov","quote":"You might get it with chemotherapy before surgery to help shrink the tumor so that it can be removed more easily during surgery.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Early high-risk triple-negative breast cancer","price_from":18000,"recovery":"Outpatient infusions every 3 weeks; fatigue for days."},{"id":"pd-1","name":"PD-1/PD-L1 inhibitor plus chemotherapy, metastatic","how_it_works":{"id":"H1","text":"Immunotherapy may be combined with chemotherapy for metastatic or recurrent breast cancer","source":{"url":"https://www.cancer.gov/types/breast/treatment/immunotherapy","host":"cancer.gov","quote":"Immunotherapy may also be given with chemotherapy for metastatic breast cancer or recurrent breast cancer that cannot be removed by surgery.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"PD-L1-positive metastatic triple-negative breast cancer","price_from":20000,"recovery":"Outpatient infusions every 3-4 weeks until progression."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"You need a treatment that reaches cancer cells throughout the body","name":"Chemotherapy","source":{"url":"https://www.cancer.gov/types/breast/treatment","host":"cancer.gov","quote":"Systemic treatments , such as chemotherapy, are drugs that can reach cancer cells throughout the body.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200},"operation_id":37},{"id":"A2","text":"Your treatment needs to target the area with cancer","name":"Radiation therapy","source":{"url":"https://www.cancer.gov/types/breast/treatment","host":"cancer.gov","quote":"Local treatments , such as surgery and radiation, are directed at the area with cancer and not the whole body.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200},"operation_id":null}],"checked_at":"2026-11-13","next_check_at":"2027-11-13","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-11","next_check_at":"2027-02-09"},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"UK passport holders can travel to Italy without a visa for up to 90 days in any 180-day period","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/entry-requirements","host":"gov.uk","quote":"You can travel without a visa to the Schengen area , which includes Italy, for up to 90 days in any 180-day period.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"visa","audience":"us","volatile":true,"text":"U.S. citizens may enter Italy without a visa for up to 90 days for tourist or business purposes","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"U.S. citizens may enter Italy for up to 90 days for tourist or business purposes without a visa.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"passport_validity","audience":"uk","volatile":true,"text":"A UK passport must expire at least 3 months after the day you plan to leave the Schengen area","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/entry-requirements","host":"gov.uk","quote":"have an ‘expiry date’ at least 3 months after the day you plan to leave the Schengen area (the expiry date does not need to be within 10 years of the date of issue)","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"passport_validity","audience":"us","volatile":true,"text":"A U.S. passport must be valid for at least 3 months beyond the period of stay in Italy","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"Your passport must be valid for at least 3 months beyond the period of stay.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V5","item":"medicines","audience":"all","volatile":false,"text":"Foreigners may bring personal medications for 30 days into Italy; bringing a copy of the prescription is recommended","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"According to the Ministry of Health, foreigners entering Italy are allowed to bring personal medications for a period of 30 days, but it is recommended that travelers also bring a copy of their prescription with them.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V6","item":"ghic","audience":"uk","volatile":false,"text":"A UK GHIC or EHIC is needed to get medically necessary state healthcare in Italy","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/health","host":"gov.uk","quote":"To get medically necessary state healthcare in Italy, you need a Global Health Insurance Card ( GHIC ) or a European Health Insurance Card ( EHIC ).","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V7","item":"hospital_payment","audience":"all","volatile":false,"text":"Private hospitals in Italy usually require advance payment or proof of adequate insurance before admitting a patient","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"Private hospitals usually require advance payment or proof of adequate insurance before admitting a patient.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V8","item":"emergency_number","audience":"all","volatile":false,"text":"Dial 118 and ask for an ambulance in Italy","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/health","host":"gov.uk","quote":"Dial 118 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["austria","azerbaijan","china","germany","greece","india","israel","latvia","malaysia","mexico","republic-of-korea","spain","switzerland","thailand","turkey","ukraine"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.6,"count":71,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>Immunotherapy for breast cancer in Italy averages from _op_713_price_from_ to _op_713_price_to_ per course. Costs depend on the specific drug protocols, clinic tier, and the patient's diagnostic profile. In the US, similar treatments cost _price_compare_US_average_ on average. Italy offers savings of approximately _price_percent_discount_%. This treatment typically includes specialist consultations, drug administration, and laboratory monitoring.</p>\n\n<ul>\n<li><strong>Private facility fees:</strong> Private clinic courses often range between 15-20% higher in northern medical hubs.</li>\n<li><strong>Specialist consultations:</strong> Initial oncology evaluations for immunotherapy typically cost between $280 and $300.</li>\n<li><strong>Remote second opinions:</strong> Leading research hospitals provide expert document reviews for approximately $400.</li>\n<li><strong>Comprehensive treatment:</strong> Total packages including surgery and systemic therapy may reach $24,500.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> Choosing a research-heavy center like San Raffaele in Milan offers exceptional value. Dr. Bianchini Giampaolo at San Raffaele leads immunotherapy research with over 100 clinical trials. Treatment there typically runs about $6,500 to $13,500 per course. This clinic holds IRCCS accreditation from the Italian Ministry of Health. Patients access cutting-edge protocols at significantly lower rates than US university hospitals.</p>","faq":[{"q":"How safe is immunotherapy for breast cancer in Italy, and what are the main risks?","a":"<p>Immunotherapy for breast cancer in Italy is highly safe when managed at specialized IRCCS research hospitals or dedicated Breast Units. These centers follow strict Italian Medicines Agency protocols. Safety depends on mandatory pre-treatment PD-L1 testing and weekly blood monitoring to manage immune-related side effects early.</p> <ul> <li><strong>Specialized supervision:</strong> Leading centers like San Raffaele in Milan use multidisciplinary teams and PDTA pathways.</li> <li><strong>Monitoring protocols:</strong> Weekly blood tests identify early signs of pneumonitis or liver inflammation effectively.</li> <li><strong>Mandatory testing:</strong> Doctors require PD-L1 testing to ensure treatment suitability and minimize unnecessary risks.</li> <li><strong>Common reactions:</strong> Fatigue and skin rashes are frequent but usually manageable without stopping therapy.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Italian research hospitals like San Raffaele lead global clinical trials for rare immune disorders. This deep expertise translates to superior safety for breast cancer patients. Their specialists often use custom-designed monitoring methods that catch potential organ inflammation before symptoms even appear.</p> <p><strong>Patient Consensus:</strong> Patients emphasize that side effects like thyroiditis or colitis can occur months after finishing. They recommend having prescribed steroids ready and choosing clinics with extensive immunotherapy experience for better risk management.</p>"},{"q":"What survival or response-rate results can breast-cancer patients expect from immunotherapy in Italy?","a":"<p>Breast cancer patients in Italy eligible for immunotherapy see response rates near 50 percent. For triple-negative breast cancer, combined immunotherapy and chemotherapy achieve a 64.8 percent pathologic complete response. Specialized centers in Milan utilize checkpoint inhibitors to extend median survival for metastatic cases from 16 to 23 months.</p> <ul> <li><strong>Triple-negative response:</strong> Combined treatments reach 64.8 percent response versus 51.2 percent for chemotherapy alone.</li> <li><strong>Metastatic survival:</strong> Median survival increases to 23 months for PD-L1-positive patients using pembrolizumab protocols.</li> <li><strong>Five-year outlook:</strong> Long-term survival rates improved from 21 percent to 30 percent since 2017.</li> <li><strong>Expert centers:</strong> Facilities like San Raffaele lead advanced translational research and immunotherapy clinical trials.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While response rates are promising, the real value in Italy lies in the academic integration. Prof. Dr. Bianchini Giampaolo at San Raffaele leads a dedicated research group for immunotherapy. This connection to clinical trials means patients often access the newest drug combinations before they reach global markets. Italy ranks ninth globally for medical requests, reflecting high confidence in their specialized oncology departments.</p>"},{"q":"Who is eligible for immunotherapy in Italian breast-cancer programs?","a":"<p>Eligibility for breast cancer immunotherapy in Italy requires a Triple-Negative Breast Cancer diagnosis, confirmed by biopsy and specific biomarker testing. The Italian Medicines Agency authorizes treatment for early-stage cases with lymph node involvement and metastatic patients showing positive PD-L1 protein expression levels.</p> <ul> <li><strong>Tumor subtype:</strong> Must be Triple-Negative, lacking estrogen, progesterone, and HER2-positive receptors.</li> <li><strong>Metric thresholds:</strong> Metastatic cases require a specific PD-L1 Combined Positive Score of 10 or higher.</li> <li><strong>Clinical stage:</strong> Early-stage tumors over 2 cm qualify for neoadjuvant therapy before surgical intervention.</li> <li><strong>Health status:</strong> Patients need an ECOG performance status of 0 to 1 for intensive treatment.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Clinical research activity directly impacts access in Italy beyond standard regulations. Leading centers like San Raffaele in Milan combine medical assistance with IRCCS-accredited research. Specialist Dr. Bianchini Giampaolo coordinates over 100 clinical trials and holds patents for identifying drug response. This high-volume research environment allows patients who fail AIFA criteria to access innovative genomic-based therapies through compassionate use programs.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the urgency of early PD-L1 and MSI testing. Practical experience shows younger patients often face fewer exclusions during clinical trial enrollment compared to older individuals with comorbidities.</p>"},{"q":"Who actually prescribes and monitors immunotherapy in Italy—oncologist, hospital, or network?","a":"<p>In Italy, the hospital-based medical oncologist is the authorized professional for prescribing and monitoring immunotherapy. They work within accredited centers to evaluate patients against Italian Medicines Agency (AIFA) criteria. Treatment is strictly hospital-based through multidisciplinary oncology groups rather than private pharmacy-filled prescriptions.</p> <ul> <li><strong>Oncologist's role:</strong> Leads the clinical care pathway and manages medication selection and dosages.</li> <li><strong>Hospital authority:</strong> Administration occurs only in Ministry of Health or JCI-accredited medical facilities.</li> <li><strong>Multidisciplinary teams:</strong> Specialists like radiologists and surgeons collaborate within hospital oncology groups.</li> <li><strong>Regional networks:</strong> Oncology networks ensure standardized care pathways across Italy's regional health systems.</li> <li><strong>Regulatory oversight:</strong> The Italian Medicines Agency governs drug eligibility and centralized high-cost drug management.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Italian centers like San Raffaele in Milan hold IRCCS status, combining clinical treatment with advanced research. This dual role is crucial for immunotherapy. Surgeons there, like Bianchini Giampaolo, also lead translational research groups. This integration allows patients to access cutting-edge protocols and clinical trials directed by their primary treating oncologists. This level of institutional integration often leads to higher oversight during complex treatments.</p>"},{"q":"How many cycles are given, and what is the on-treatment and recovery timeline?","a":"<p>Immunotherapy for breast cancer in Italy typically involves cycles every 2 to 4 weeks, with most protocols spanning 6 to 12 months. Treatment duration depends on cancer stage and drug response, often administered at research centers like San Raffaele in Milan.</p> <ul> <li><strong>Cycle duration:</strong> Each infusion cycle usually lasts 14 to 28 days.</li> <li><strong>Treatment frequency:</strong> Patients receive drugs on a single day per cycle.</li> <li><strong>Initial recovery:</strong> Side effects like fatigue often improve 2 to 3 weeks post-session.</li> <li><strong>Long-term timeline:</strong> Full stamina recovery often takes 6 to 12 months after completion.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Italian centers like San Raffaele act as major IRCCS research hubs. Dr. Bianchini Giampaolo has managed over 100 clinical trials here. This high trial volume means patients often access the latest combination therapies before they reach smaller clinics. Most patients save around _price_percent_discount_% compared to US averages while receiving these academic-grade treatments.</p>"},{"q":"What diagnostic tests and biopsies are done before starting immunotherapy?","a":"<p>Diagnostic protocols for breast cancer immunotherapy include biomarker testing via core needle biopsy to measure PD-L1 expression and MSI/MMR status. Italian oncology centers perform baseline imaging like PET/CT scans and brain MRIs alongside liver, kidney, and thyroid function blood panels to ensure patient safety.</p> <ul> <li><strong>Biomarker expression:</strong> IHC staining measures PD-L1 levels on tumor cells to predict treatment response.</li> <li><strong>Genetic profiling:</strong> Tests identify Microsatellite Instability (MSI) and Mismatch Repair (MMR) defects in DNA.</li> <li><strong>Metastatic screening:</strong> CT scans of the chest and abdomen rule out spread before starting.</li> <li><strong>Organ health:</strong> Mandatory thyroid panels and heart ECHO cardiograms establish necessary baseline function.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Italian research hospitals like San Raffaele emphasize PD-L1 CPS scores over 10 for treatment eligibility. Dr. Bianchini Giampaolo, a lead researcher in Milan, uses these specific patent-based metrics to predict drug success. This high-level specialization often results in more precise patient selection than general oncology protocols.</p> <p><strong>Patient Consensus:</strong> Patients emphasize requesting extra biopsy tissue blocks during initial diagnosis. This prevents delays of 2 to 4 weeks if initial samples prove insufficient for mandatory PD-L1 staining requirements.</p>"},{"q":"How long do international patients need to stay in Italy to complete the first evaluation and start therapy?","a":"<p>International patients typically spend 1 to 3 weeks in Italy for initial breast cancer immunotherapy evaluation and treatment commencement. This timeframe covers multidisciplinary team reviews and personalized biomarker testing. Centers like San Raffaele in Milan require pre-arrival record submission to expedite the on-site process.</p> <ul> <li><strong>Pre-arrival preparation:</strong> Submit pathology and imaging digital records 4 to 6 weeks before traveling.</li> <li><strong>Evaluation timeline:</strong> Specialists often complete the initial on-site assessment within 2 working days.</li> <li><strong>Treatment blocks:</strong> Therapy cycles usually occur in 1-week blocks before patients can travel home.</li> <li><strong>Legal requirements:</strong> Non-EU patients must apply for residence permits for stays exceeding 90 days.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Patients can minimize their stay in Milan by scheduling a teleconsult with specialists like Dr. Bianchini Giampaolo beforehand. Data shows that San Raffaele's status as an IRCCS research hospital provides unique access to translational protocols. This often allows for faster internal biomarker profiling than smaller regional clinics can offer.</p> <p><strong>Patient Consensus:</strong> Travelers emphasize that budget stays of 3 to 6 weeks are safer for non-EU residents. They frequently suggest preparing proof of funds early in case hospital administrative waits exceed initial estimates.</p>"}],"h2":[{"text":"How Much Does Immunotherapy for breast cancer Cost in Italy?","kind":"content"},{"text":"Your Benefits and Guarantees with Bookimed","kind":"content"},{"text":"Your personal Bookimed medical coordinator","kind":"content"},{"text":"Discover the Best Immunotherapy for breast cancer Clinics in Italy: 1 Verified Option and Prices","kind":"content"},{"text":"Immunotherapy for breast cancer Overview in Italy","kind":"content"},{"text":"Our Doctors","kind":"content"},{"text":"Video Stories from Bookimed Patients","kind":"ui"},{"text":"Reviews about Bookimed: Discover Patients' Insights","kind":"ui"},{"text":"Share this content","kind":"ui"},{"text":"FAQ about Immunotherapy for breast cancer in Italy","kind":"content"},{"text":"Get a free consultation","kind":"ui"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}